MetaCap

Assembly Biosciences (ASMB) vs Neurogene (NGNE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neurogene (NGNE) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 10.4% versus a loss of 42.4%. Over five years, ASMB leads with a -21.3% price change compared with -78.3% for NGNE. Neurogene is the larger company by market cap ($458.5 million vs $454.4 million), about 1.0 times the size, while Assembly Biosciences is growing revenue faster (+153.5% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-42.36%NGNE+10.42%
+122%+32%-57%
Nov 21, 20251 yearNov 20, 2026
ASMB-19.60%NGNE-79.10%
+46%-26%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus NGNE key metrics
MetricASMBNGNE
Share price$22.19$22.15
Market cap$454.39M$458.53M
1-day change-1.38%-3.40%
YTD return-34.75%+7.52%
1-year return-42.36%+10.42%
5-year return-21.31%-78.33%
P/E ratio (TTM)29.59—
EPS (TTM)$0.75$-5.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.30M$0
Revenue growth (YoY)+153.52%-100.00%
Net income (latest FY)$-6.12M$-90.35M
Operating margin-16.76%—
Net margin-8.47%—
52-week high$39.65$43.66
52-week low$19.20$15.93
Distance from 52-week high-44.04%-49.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+130.73%+250.47%
Average volume309.38K307.78K
Shares outstanding20.48M20.70M
Employees73131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NGNE has outperformed ASMB by 52.8 percentage points over the past year.
  • Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -100.00%).

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Neurogene

NGNE stock →

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

ASMB vs NGNE FAQ

Which is bigger, Assembly Biosciences or Neurogene?

Neurogene (NGNE) is larger, with a market capitalization of $458.53M compared with $454.39M for Assembly Biosciences (ASMB).

Which stock has performed better over the past year, ASMB or NGNE?

NGNE returned +10.42% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.

Are Assembly Biosciences and Neurogene in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons